Description: Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. Oncodesign Société Anonyme has a strategic partnership with InterSystems for new treatments in the field of oncology; and Covalab. The company also has a collaboration agreement with TiumBio Co., Ltd. for the research and development of fibrosis drug candidates. Oncodesign Société Anonyme was founded in 1995 and is headquartered in Dijon, France.
Home Page: www.oncodesign.com
20 rue Jean Mazen
Dijon,
21076
France
Phone:
33 3 80 78 82 60
Officers
| Name | Title |
|---|---|
| Dr. Philippe Genne Ph.D. | Founder, Chairman, CEO & Chief Corp. Bus. Devel. Officer |
| Mr. Arnaud Lafforgue | Chief Financial & Admin. Officer |
| Dr. Jan Hoflack Ph.D. | Chief Scientific Officer, Deputy MD & Member of Exec. Board |
| Ms. Catherine Genne | Deputy Managing Director, Member of the Exec. Board & Director |
| Mr. Olivier Duchamp | Member of Exec. Board |
| Mr. Francis Bichat | Member of Exec. Board |
| Ms. Karine Lignel | Chief Operating Officer |
| Mr. Stephane Gerart | Chief Information Officer & Head of Artificial Intelligence |
| Ms. Sylvie Fernandes Forster | Chief Legal Officer |
| Mr. Thierry Billoue | Chief HR Officer |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 63.2456 |
| Price-to-Book MRQ: | 19.0349 |
| Price-to-Sales TTM: | 3.0511 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 230 |